Qsymia is a weight-loss prescription medication that combines the appetite suppressant phentermine with the anti-seizure and anti-migraine drug topiramate.
Qsymia is clinically proven to help with weight loss and is approved by the Food and Drug Administration (FDA) for use in adults with a Body Mass Index (BMI) greater than 30, or a BMI greater than 27 with at least one weight-related condition such as high blood pressure or type 2 diabetes. The medication works by curbing cravings and suppressing hunger, which can lead to a lower caloric intake and eventual weight loss.
Qsymia is taken orally once a day, with an initial dose of 3.75 mg/23 mg for 14 days, followed by a maintenance dose of 7.5 mg/46 mg. The medication should be taken in the morning to avoid potential insomnia caused by the stimulant phentermine.
Qsymia is classified as a Schedule IV controlled substance because of the phentermine content, which means it has a lower risk of abuse compared to Schedule II substances such as opioids and amphetamines. However, it can still cause side effects such as dizziness, dry mouth, and constipation. More serious side effects include increased heart rate and suicidal thoughts or behavior, but these are rare. Qsymia should not be taken by pregnant women due to the risk of birth defects, and should be used with caution by those with a history of mental health issues.
Qsymia is a weight-loss medication that has been clinically proven to be effective in helping patients achieve their weight loss goals. While it does come with potential side effects and should be used with caution by certain individuals, it can be a useful tool in conjunction with a healthy diet and regular exercise for those struggling to lose weight. As with any medication, patients should consult with their healthcare provider to determine if Qsymia is right for them.